Neoral approved for treatment of sight-threatening uveitis

Neoral (ciclosporin) can now be used for severe refractory non-infective uveitis and uveitis assocated with Behcet's disease.

Behcet’s disease is a rare autoimmune disorder that causes mouth and genital ulceration and inflammation of the eye (pictured) | SUE FORD/SCIENCE PHOTO LIBRARY
Behcet’s disease is a rare autoimmune disorder that causes mouth and genital ulceration and inflammation of the eye (pictured) | SUE FORD/SCIENCE PHOTO LIBRARY

Neoral can be considered in sight-threatening intermediate or posterior non-infective uveitis that is sight-threatening and has not responded to conventional treatment (usually corticosteroids) or when such treatment is not tolerated. 

It can also be used in uveitis associated with Behcet’s disease, a rare autoimmune disorder which causes systemic vasculitis and often presents with ocular problems and membrane ulceration. It can only be used in Behcet’s uveitis if there are repeated inflammatory attacks that threaten the retina and provided there are no neurological manifestations.

For both indications, Neoral should be initiated at 5mg/kg daily in two divided doses and continued until remission of uveal inflammation and an improvement of visual acuity is observed. The initial dose may be increased to 7mg/kg/day for a limited period in refractory cases. To help achieve remission or to counteract inflammatory ocular attacks, adjunctive corticosteroids may be given. For maintenance treatment, the ciclosporin dose should be slowly reduced to the lowest effective dose (max 5mg/kg/day).

No blood drug monitoring required

There is no need to routinely monitor blood ciclosporin levels when treating uveitis but these should be monitored in patients with severe hepatic impairment until stable and within the target range. Monitoring may also be considered if co-administered with drugs that affect the pharmacokinetics of ciclosporin (eg, CYP3A4 inducers, inhibitors or substrates). 

Contraindicated in renal impairment

Owing to the nephrotoxic nature of ciclosporin, Neoral should not be used to treat uveitis in patients with renal impairment and renal function must be assessed in all patients before starting (using at least two measurements) and monitored throughout treatment.

View Neoral drug record

Further information: Novartis

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...